1. Home
  2. IMRN vs SUGP Comparison

IMRN vs SUGP Comparison

Compare IMRN & SUGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • SUGP
  • Stock Information
  • Founded
  • IMRN 1994
  • SUGP 1998
  • Country
  • IMRN Australia
  • SUGP Hong Kong
  • Employees
  • IMRN N/A
  • SUGP N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • SUGP
  • Sector
  • IMRN Health Care
  • SUGP
  • Exchange
  • IMRN Nasdaq
  • SUGP NYSE
  • Market Cap
  • IMRN 9.2M
  • SUGP 9.6M
  • IPO Year
  • IMRN N/A
  • SUGP 2024
  • Fundamental
  • Price
  • IMRN $1.88
  • SUGP $0.50
  • Analyst Decision
  • IMRN Strong Buy
  • SUGP
  • Analyst Count
  • IMRN 1
  • SUGP 0
  • Target Price
  • IMRN $5.00
  • SUGP N/A
  • AVG Volume (30 Days)
  • IMRN 25.2K
  • SUGP 146.6K
  • Earning Date
  • IMRN 07-07-2025
  • SUGP 07-21-2025
  • Dividend Yield
  • IMRN N/A
  • SUGP N/A
  • EPS Growth
  • IMRN N/A
  • SUGP 1.19
  • EPS
  • IMRN N/A
  • SUGP 0.11
  • Revenue
  • IMRN $4,048,286.00
  • SUGP $23,446,259.00
  • Revenue This Year
  • IMRN N/A
  • SUGP N/A
  • Revenue Next Year
  • IMRN N/A
  • SUGP N/A
  • P/E Ratio
  • IMRN N/A
  • SUGP $4.70
  • Revenue Growth
  • IMRN 82.90
  • SUGP 11.29
  • 52 Week Low
  • IMRN $1.50
  • SUGP $0.35
  • 52 Week High
  • IMRN $2.87
  • SUGP $3.25
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 58.70
  • SUGP 34.00
  • Support Level
  • IMRN $1.68
  • SUGP $0.47
  • Resistance Level
  • IMRN $1.94
  • SUGP $0.66
  • Average True Range (ATR)
  • IMRN 0.09
  • SUGP 0.08
  • MACD
  • IMRN 0.02
  • SUGP -0.02
  • Stochastic Oscillator
  • IMRN 76.92
  • SUGP 30.36

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About SUGP SU GROUP HLDGS LTD

SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.

Share on Social Networks: